Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
Artiva Biotherapeutics, Inc. (ARTV)
Company Research
Source: GlobeNewswire
SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc. Dr. Banerjee will succeed Thorsten Graef, M.D., Ph.D., who will continue as a strategic advisor to the Company. “We are pleased to welcome Dr. Banerjee to Artiva as we focus clinical development of our AlloNK® program on the treatment of B-cell driven autoimmune diseases. Dr. Banerjee, together w
Show less
Read more
Impact Snapshot
Event Time:
ARTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTV alerts
High impacting Artiva Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTV
News
- Wedbush Predicts Up to ~600% Jump for These 2 ‘Strong Buy' Stocks [Yahoo! Finance]Yahoo! Finance
- Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.MarketBeat
- Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Artiva Biotherapeutics GAAP EPS of -$0.88 [Seeking Alpha]Seeking Alpha
- Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease [Yahoo! Finance]Yahoo! Finance
ARTV
Sec Filings
- 12/15/25 - Form 4
- 12/15/25 - Form 144
- 12/12/25 - Form 4
- ARTV's page on the SEC website